Eric Edidin

Spartacus Acquisition Corporation is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any business industry or sector, it intends to focus its search on telecommunications, media and technology (TMT) companies. The Company's units are listed on the Nasdaq Capital Market under the ticker symbol TMTSU.

ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.

Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasomes Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocytes natural regulatory functions.

Capillary Biomedical, Inc. (CapBio) is a medical device startup developing technologies for diabetes management. We aim to dramatically simplify insulin delivery, reducing the burden on both patients and the overall healthcare system. CapBios first product is the patent-pending SteadiSet infusion set for insulin pump therapy. Its SteadiFlow technology features a kink-proof, super-soft cannula with multi-port delivery designed for reliable and comfortable insulin delivery. Our user-friendly insertion device makes it easy. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA. This ongoing academic-industry collaboration is focused on improving the comfort, reliability and predictability of insulin infusion therapy. Together, we aim to achieve more consistent and reliable insulin absorption, which will enable people with diabetes to achieve improved blood glucose control.

The GVNG Platform empowers corporations to launch a "For Purpose" Digital Nonprofit that turbocharges their CSR, Social Impact and Corporate Giving; creating unprecedented opportunities to align and integrate core business solutions, human resources, and constituent engagement for GOOD. Forbes refers to GVNG as “one of the most revolutionary platforms in the social impact space today” and describes GVNG as the “Shopify for Nonprofits.” The GVNG Digital Nonprofit is administered by GVNGorg, a 501(c)(3) tax-exempt organization (a California nonprofit public benefit corporation) and is powered by Benefactis.

Cecelia Health is a virtual specialty clinic for people with chronic conditions, delivering virtual care designed with a human element to improve adherence and health outcomes. ​ From millions of connections led by a national network of specialty providers and expert clinicians, we understand how to motivate people to make lasting behavior change through scalable solutions that address individual needs. We offer a new approach to modernize the care journey by amplifying human engagement and delivering a seamless patient experience that is proven to positively impact quality measures, reduce variability in care, and improve medication, device, and clinical trial adherence. ​ What started as a desire to help people living with diabetes access personalized support is now a human-led virtual clinic that is transforming the healthcareUX. For health plans, employers, health systems, and providers, we complement existing care management programs and close critical care gaps; for pharma, device manufacturers and distributors, and clinical trial organizations, we offer proven patient support programs that optimize engagement and increase medication adherence and persistency.​ Beyond any digital-only solution or call center, we expand access to care and provide life-changing support from dedicated clinical experts through our virtual specialty clinic, remote patient monitoring, education, and device training powered by first party data and robust analytics.​ Current job openings at Cecelia Health are listed on our careers page. We will never ask you to provide sensitive financial or personal information throughout the recruitment or interview process. Cecelia Health will never extend a job offer without interviewing candidates via phone/video.

Mellitus Health’s decision support software, Insulin Insights™, offers precision insulin prescription adjustment recommendations to clinicians in just seconds. The software automates and expands algorithms that are based on 35 years of published clinical research by Mayer B. Davidson, MD, past editor-in-chief of Diabetes Care and a past president of the American Diabetes Association. Unique in the market, the solution works with all eight standard insulin regimens and all types of insulins. It addresses nearly every dosing scenario imaginable. The FDA-cleared and CE-registered solution accepts readings from all major glucometer brands and integrates seamlessly into existing clinical workflows. A recent study showed a 2.4% drop in participants’ HbA1c at 180 days, with no severe hypoglycemia and no change in patient behavior. (1) Founded in 2014 as Insulin Algorithms by Mayer B. Davidson, MD; Josh Davidson; and Michael Margolese, the Los Angeles firm rebranded in 2018 as Mellitus Health, Inc. (1) Davidson MB, Davidson SJ. Effect of remote glucose monitoring utilizing computerized insulin dose adjustment algorithms on A1C levels: a preliminary report. Diabetes 67 (Suppl 1): A234, 2018.

Spartacus Acquisition Corporation is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any business industry or sector, it intends to focus its search on telecommunications, media and technology (TMT) companies. The Company's units are listed on the Nasdaq Capital Market under the ticker symbol TMTSU.

ILiAD Biotechnologies is utilizing its B-Tech vector platform to develop next generation vaccines to eradicate infectious diseases and improve lives. Its lead candidate, BPZE1, which has completed Phase 2 clinical trials, is the most advanced next generation vaccine for the prevention of whooping cough, a serious illness caused by Bordetella pertussis.

Diasome Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasomes Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocytes natural regulatory functions.

Capillary Biomedical, Inc. (CapBio) is a medical device startup developing technologies for diabetes management. We aim to dramatically simplify insulin delivery, reducing the burden on both patients and the overall healthcare system. CapBios first product is the patent-pending SteadiSet infusion set for insulin pump therapy. Its SteadiFlow technology features a kink-proof, super-soft cannula with multi-port delivery designed for reliable and comfortable insulin delivery. Our user-friendly insertion device makes it easy. The company is based in Irvine, CA and is a spin-out of the Artificial Pancreas Center at the Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, PA. This ongoing academic-industry collaboration is focused on improving the comfort, reliability and predictability of insulin infusion therapy. Together, we aim to achieve more consistent and reliable insulin absorption, which will enable people with diabetes to achieve improved blood glucose control.